Brought to you by 
ProStrakan pays GTx $21.7mm for US rights to Fareston
05 Nov 2012
Executive Summary
GTx Inc. (cancer and cancer supportive care therapeutics) has licensed ProStrakan Group PLC, the specialty pharma division of Kyowa Hakko Kirin Co. Ltd., exclusive US rights to the breast cancer drug Fareston (toremifene, 60mg tablets). ProStrakan paid $21.7mm in cash ($19mm net of related expenses).
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
ProStrakan pays GTx $21.7mm for US rights to Fareston
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice